Navigation path

MuNanoVac


HIV/AIDS

Mucosal Nano Vaccine Candidate for HIV
Framework programme:
6
Call:
4
Project number:
LSHP-CT-2006-037200
EC contribution:
€ 1, 505,702
Duration:
36 Months
Type:
STREP
Starting date:
January 2007

Keywords:Vaccines, Immunology and Infections
Free keywords:
HIV/AIDS, Immune response, Vaccine strategy, Mucosa, Skin, Poly (Lactic Acid), PLA, Nanoparticle and Biodegradable carrier

Summary:

The MuNanoVac STREP project will assess a new vaccine strategy to prevent HIV-1 infection based on a primo-vaccination using a biodegradable synthetic colloidal carrier made of poly-lactic acid (PLA) nanoparticles covered with adsorbed antigens. The aim is to demonstrate that PLA nanoparticles are a perfect transcutaneous or mucosal vaccine vehicle, immunogenic for both arms of immunity and adaptable to many types of antigens as well as easy and simple to produce.

Such nanoparticle-based vaccine carriers will allow targeting dentritic cells or transporting the vaccine through skin or mucosal epithelial barriers. To amplify the mucosal immune response, the project will investigate the potential use of immunomodulator molecules associated with the comparison of two different immunisation routes.

Moreover, the MuNanoVac project will contribute to advancing a promising vaccine approach for HIV that could also prove versatile enough for application to other poverty-related diseases such as tuberculosis. With the proposed vaccine candidate, the project gives Europe a tremendous opportunity to gain leadership in the use of biodegradable nanoparticles for vaccine carriers.

[+] Read More